Bayer and Onyx announced that they have submitted Nexavar to the FDA for approval to treat a common form of liver disease. Researchers are also planning a late-stage study of the cancer drug as an adjuvant treatment of hepatocellular carcinoma following the complete removal of early stage liver cancer. Release [1]
Links:
[1] http://www.fiercebiotech.com/node/7417